Search Results - "Maddocks, K. J."

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells by Zhong, Y, El-Gamal, D, Dubovsky, J A, Beckwith, K A, Harrington, B K, Williams, K E, Goettl, V M, Jha, S, Mo, X, Jones, J A, Flynn, J M, Maddocks, K J, Andritsos, L A, McCauley, D, Shacham, S, Kauffman, M, Byrd, J C, Lapalombella, R

Get full text

The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model by Beckwith, K A, Frissora, F W, Stefanovski, M R, Towns, W H, Cheney, C, Mo, X, Deckert, J, Croce, C M, Flynn, J M, Andritsos, L A, Jones, J A, Maddocks, K J, Lozanski, G, Byrd, J C, Muthusamy, N

“…Therapeutic regimens for chronic lymphocytic leukemia (CLL) have increasingly utilized monoclonal antibodies since the chimeric anti-CD20 antibody rituximab…”
Get full text

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia by Rogers, K A, Ruppert, A S, Bingman, A, Andritsos, L A, Awan, F T, Blum, K A, Flynn, J M, Jaglowski, S M, Lozanski, G, Maddocks, K J, Byrd, J C, Woyach, J A, Jones, J A

“…Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AICs). Ibrutinib is an irreversible inhibitor of Bruton’s…”
Get full text

Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND) by Sehn, L. H., Kuruvilla, J., Salles, G., Maddocks, K. J., Koch, C., Xue, Z., Amoloja, T., Amin, A., Duell, J.

Get full text

Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma by Duell, J., Abrisqueta, P., Dreyling, M., Gaidano, G., Barca, E. G., Jurczak, W., Maddocks, K. J., Menne, T., Nagy, Z., Tournilhac, O., Bakuli, A., Amin, A., Gurbanov, K., Salles, G.

Get full text

Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study by Duell, J., Abrisqueta, P., Andre, M., Augustin, M., Gaidano, G., Barca, E. G., Jurczak, W., Kalakonda, N., Liberati, A. M., Maddocks, K. J., Menne, T., Nagy, Z., Tournilhac, O., Bakuli, A., Amin, A., Gurbanov, K., Salles, G.

Get full text

LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL) by Duell, J, Maddocks, K. J, González‐Barca, E, Jurczak, W, Liberati, A. M, Obr, A, Gaidano, G, Abrisqueta, P, André, M, Dreyling, M, Menne, T, Dirnberger‐Hertweck, M., Weirather, J, Ambarkhane, S, Salles, G

Get full text

CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL) by LaCasce, A. S., Dockter, T., Ruppert, A., Kostakoglu, L., Schöder, H., Hsi, E. D., Bogart, J. A., Cheson, B. D., Wagner‐Johnston, N. D., Abramson, J. S., Maddocks, K. J., Leonard, J. P., Bartlett, N. L.

Get full text

SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA by Karmali, R., Donovan, A., Wagner‐Johntson, N., Messmer, M., Mehta, A., Anderson, J. K., Reddy, N., Kovach, A. E., Landsburg, D. J., Glenn, M., Inwards, D. J., Ristow, K., Lansigan, F., Kaplan, J. B., Caimi, P. B., Rajguru, S., Evens, A., Klein, A., Umyarova, E., Amengual, J. E., Lue, J. K., Diefenbach, C., Epperla, N., Barta, S. K., Hernandez‐Ilizaliturri, F. J, Handorf, E., Villa, D., Gerrie, A. S., Li, S., Mederios, J., Wang, M., Cohen, J., Calzada, O., Churnetski, M., Hill, B., Sawalha, Y., Gerson, J. N., Kothari, S., Vose, J. M., Bast, M., Fenske, T. S., Narayana Rao Gari, S., Maddocks, K. J., Bond, D., Bachanova, V., Kolla, B., Chavez, J., Shah, B.

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Sehn, L H, Kuruvilla, J, Salles, G, Maddocks, K J, Koch, C, Xue, Z, Amoloja, T, Amin, A, Duell, J

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Duell, J, Abrisqueta, P, Dreyling, M, Gaidano, G, Barca, E G, Jurczak, W, Maddocks, K J, Menne, T, Nagy, Z, Tournilhac, O, Bakuli, A, Amin, A, Gurbanov, K, Salles, G

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Duell, J, Abrisqueta, P, Andre, M, Augustin, M, Gaidano, G, Barca, E G, Jurczak, W, Kalakonda, N, Liberati, A M, Maddocks, K J, Menne, T, Nagy, Z, Tournilhac, O, Bakuli, A, Amin, A, Gurbanov, K, Salles, G

Get full text

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma by Wang, Yucai, Larson, Melissa C., Farooq, Umar, Ekberg, Sara, Ekstroem Smedby, Karin, Simonsen, Mikkel Runason, Niemann, Carsten Utoft, Zhao, Eric J., Gerrie, Alina S., Switchenko, Jeffrey M., Bond, David A., Bachanova, Veronika, Barta, Stefan K., Hill, Brian T., Martin, Peter, Danilov, Alexey, Grover, Natalie S., Karmali, Reem, Ghosh, Nilanjan, Fenske, Timothy S., Kahl, Brad S., Albertsson-Lindblad, Alexandra, Glimelius, Ingrid Cecilia, Ludvigsen Al-Mashhadi, Ahmed, Stauffer Larsen, Thomas, Maddocks, Kami J., Link, Brian K., Paludo, Jonas, Nowakowski, Grzegorz S., Habermann, Thomas M., Maurer, Matthew J., Villa, Diego, Cohen, Jonathon B., El-Galaly, Tarec Christoffer Christoffer, Jerkeman, Mats, Cerhan, James R.

“…Background: Event-free survival at 24 months (EFS24) after frontline immunochemotherapy (IC) is an important endpoint in diffuse large B-cell lymphoma and…”
Get full text

Exclusion of maltodextrins from phosphatidylcholine multilayers during dehydration: effects on membrane phase behaviour by Koster, Karen L, Maddocks, Kami J, Bryant, Gary

“…The effect of increasing solute size on phosphatidylcholine phase behaviour at a range of hydrations was investigated using differential scanning calorimetry…”
Get full text